Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bone supplement may speed fracture healing in new trial

NCT ID NCT07210281

Disease control Sponsor: University of Opole Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a supplement called ossein-hydroxyapatite complex (Osteogenon) can help broken bones heal better and faster. Researchers will track 150 adults with fractures to see if the supplement improves bone union, reduces pain, and supports recovery. The goal is to find a safe, supportive treatment to improve fracture healing outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * no contraindications to taking Osteogenon * a follow-up period of more than 3 months after treatment completion * complete medical and radiological records * a written informed consent * not taking any other medications that could affect bone tissue remodeling * not taking other medications that interact with Osteogenon * no other limb pathologies (inflammatory or neurogenic) * absence of comorbidities that could affect bone union Exclusion Criteria: * age under 18 years or over 85 years * hypersensitivity to the active ingredient or to any of the excipients * severe renal failure and dialysis therapy * hypercalcemia * hypercalciuria * calcium-based kidney stones or tissue calcifications * a follow-up period shorter than 3 months after treatment completion * a lack of informed consent * a lack of cooperation with the patient * absent or incomplete medical and radiological records * taking medications that could affect bone tissue remodeling * taking medications that may interact with Osteogenon (e.g. thiazide diuretics) * metabolic disorders * post-traumatic skeletal deformities * neuromuscular disorders * post-inflammatory deformities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Patients with fractures are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone fracture Wrist Fractures

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Patients with fractures

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Clinical Hospital in Opole

    RECRUITING

    Opole, Opole Voivodeship, 46-020, Poland